Eckert & Ziegler stock (DE0005659700): Metzler starts coverage with Buy rating

Eckert & Ziegler, a German medtech firm focused on radiopharmaceuticals, received fresh analyst attention. Metzler launched coverage on October 30, 2025, assigning a Buy rating and €21.00 price target, implying 41% upside, Campus Berlin-Buch as of 10/30/2025. Separately, NuWays AG confirmed its Buy stance and lifted its target to €25 from €21 in a May 2026 note, citing recovering demand and cost efficiencies, Boerse Online as of 05/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Eckert & Ziegler: core business model

Eckert & Ziegler develops and manufactures products for nuclear medicine, radiation therapy and industrial applications. The company supplies radionuclides, cyclotrons and peptide-based radiopharmaceuticals used in diagnostics and therapy for cancer patients. Its portfolio spans the entire value chain from raw materials to finished doses, serving hospitals, research institutes and pharma partners globally. Eckert & Ziegler operates production sites in Germany, the US and France, with a focus on theranostics – combining therapy and diagnostics.

Main revenue and product drivers for Eckert & Ziegler

Revenue primarily comes from three segments: Pharma & Healthcare (radiopharmaceuticals), Medical Technology (therapy equipment) and Industrial & Research. In recent periods, peptide production and lutetium-177 isotopes have gained traction amid rising demand for targeted radioligand therapies. The US market contributes significantly, driven by partnerships with firms advancing prostate cancer treatments. Eckert & Ziegler reported strong order intake in transition years, positioning it for margin expansion as per analyst views.

Industry trends and competitive position

The radiopharma sector is expanding rapidly due to novel therapies like PSMA-targeted treatments for prostate cancer. Eckert & Ziegler holds a strong position as an integrated supplier of key isotopes such as actinium-225 and lead-212, which are scarce. Competitors include ITM, Novartis and smaller isotope producers, but Eckert & Ziegler's vertical integration provides a competitive edge in supply reliability. US investors note its exposure to the booming American oncology market, where radioligands are projected to reach multi-billion scale.

Why Eckert & Ziegler matters for US investors

Listed on the Frankfurt exchange, Eckert & Ziegler offers US retail investors access to Europe's radiopharma growth via OTC trading or ADRs. Its US subsidiary in Valencia, California, supports North American supply chains critical for FDA-approved therapies. With American pharma giants investing heavily in radioligands, Eckert & Ziegler's role as a key supplier ties it to US healthcare spending trends, making it relevant for portfolios seeking medtech innovation plays.

Conclusion

Recent analyst initiations by Metzler and NuWays highlight Eckert & Ziegler's potential in the radiopharma space amid recovering demand and operational improvements. The company's integrated model and US exposure position it well in a high-growth sector. Investors should monitor upcoming earnings and supply chain developments for further insights into execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.